OrganiGram (OGI) Reports Q1 Loss, Lags Revenue Estimates
OrganiGram (OGI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.14 per share a year ago.
Organigram Holdings Inc. (OGI) Q4 2024 Earnings Call Transcript
Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call December 18, 2024 8:00 AM ET Company Participants Max Schwartz - Director of IR Beena Goldenberg - CEO Tim Emberg - CCO Greg Guyatt - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Yewon Kang - Canaccord Genuity Operator Good morning. My name is Rob, and I will be your conference operator today.
OrganiGram purchasing Motif Labs to become Canada's largest cannabis company by market share, as others retreat
OrganiGram to pay up to C$100 million ($70.7 million) for vape and prerolled cannabis specialist Motif.
Organigram Could Soar In 2026
Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco. Analysts expect revenue and adjusted EBITDA to grow significantly in FY25 and FY26, making the stock a compelling buy.
Organigram: Why I Still Like It
Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential.
Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)
Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued.
Why Is Organigram (OGI) Stock Up 25% Today?
Organigram (NASDAQ: OGI ) stock is rising higher on Tuesday after the Canadian cannabis company released its most recent earnings report. The big news here is the company reporting C$41.06 million in revenue for its fiscal third quarter of the year.
Organigram Holdings Inc. (OGI) Q3 2024 Earnings Call Transcript
Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - AGP Pablo Zuanic - Zuanic & Associates Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Keyla, and I'll be your conference operator today.
Organigram's stock rises as Canadian pot company's revenue tops analyst estimate
OrganiGram Holdings Inc.'s stock OGI, -2.04% was up 4% in premarket trading Wednesday after the Canadian cannabis producer reported beter-than-expected revenue. OrganiGram swung to third-quarter net income of C$2.82 million ($2.05 million), from a loss of C$213.45 million in the year-ago quarter.
Organigram Has Declined A Lot And Is A Great Deal
Organigram stock has declined substantially, still up 16.4% in 2024, but well below its recent public offering price. Q2 report showed revenue fell 5% to C$37.6 million, with adjusted EBITDA at -C$1 million. Stock valuation is cheap at 0.8X tangible book value, potential for significant gains if analyst outlook improves.
